Bio­gen lines up po­ten­tial deal for ALS drug, dou­bling down on neu­ro­fil­a­ment bio­mark­er

Hav­ing scored a his­toric FDA ac­cel­er­at­ed ap­proval in amy­otroph­ic lat­er­al scle­ro­sis, or ALS, based on a bio­mark­er, Bio­gen is go­ing for more.

Bio­gen has teamed up with Neu­roSense Ther­a­peu­tics to study whether and how the Is­raeli biotech’s drug can­di­date, dubbed PrimeC, im­pacts lev­els of neu­ro­fil­a­ment, a pro­tein shed by dam­aged neu­rons. In late April, the FDA cleared Bio­gen’s Qal­sody (tofersen) based on this very pro­tein — de­clar­ing for the first time it could be used to pre­dict clin­i­cal ben­e­fit for the neu­rode­gen­er­a­tive dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER